3-{2-chloro-4-[3-(2,6-dichlorophenyl)-5-naphthalen-2-ylisoxazol-4-ylmethoxy]benzoylamino}benzoic acid

ID: ALA234371

Chembl Id: CHEMBL234371

PubChem CID: 24776366

Max Phase: Preclinical

Molecular Formula: C34H21Cl3N2O5

Molecular Weight: 643.91

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(O)c1cccc(NC(=O)c2ccc(OCc3c(-c4c(Cl)cccc4Cl)noc3-c3ccc4ccccc4c3)cc2Cl)c1

Standard InChI:  InChI=1S/C34H21Cl3N2O5/c35-27-9-4-10-28(36)30(27)31-26(32(44-39-31)21-12-11-19-5-1-2-6-20(19)15-21)18-43-24-13-14-25(29(37)17-24)33(40)38-23-8-3-7-22(16-23)34(41)42/h1-17H,18H2,(H,38,40)(H,41,42)

Standard InChI Key:  LFODZVYWAHZURL-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

Associated Targets(Human)

NR1H4 Tclin Bile acid receptor FXR (6228 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PGR Tclin Progesterone receptor (8562 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 643.91Molecular Weight (Monoisotopic): 642.0516AlogP: 9.65#Rotatable Bonds: 8
Polar Surface Area: 101.66Molecular Species: ACIDHBA: 5HBD: 2
#RO5 Violations: 2HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski): 2
CX Acidic pKa: 3.92CX Basic pKa: CX LogP: 9.06CX LogD: 5.85
Aromatic Rings: 6Heavy Atoms: 44QED Weighted: 0.17Np Likeness Score: -1.05

References

1. Kainuma M, Makishima M, Hashimoto Y, Miyachi H..  (2007)  Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.,  15  (7): [PMID:17292610] [10.1016/j.bmc.2007.01.046]
2. Xu Y..  (2016)  Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases.,  59  (14): [PMID:26878262] [10.1021/acs.jmedchem.5b00342]

Source